The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) Bacteriology Division is in the process of purchasing custom cytokine filters from CytoSorbents, Inc. for use in a funded project to develop new biodefense countermeasures.
The CytoSorb filters are required to test the effect the filters have as a treatment against SEB toxin exposure, anthrax and plague in non-human primate models.
The filters will be developed to match USAMRIID’s animal model and bacterial targets.
CytoSorbents is a publicly-traded, critical care immunotherapy company using blood purification to treat life-threatening illnesses. CytoSorbents’ blood purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Source: FBO.gov, CytoSorbents.com. CytoSorb is a registered, protected term of CytoSorbents Inc.
